New RA drug enters first human tests
NCT ID NCT07234773
First seen Nov 18, 2025 · Last updated May 18, 2026 · Updated 11 times
Summary
This early-stage study tests a new drug called KT501 in 24 adults with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body processes the drug after a single injection. Participants must have had RA for at least 6 months and not responded well to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kali Study Site
RECRUITINGBayswater, Australia
Conditions
Explore the condition pages connected to this study.